Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS).
Chida K, Kotani D, Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okita Y, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Shimada Y. Chida K, et al. Among authors: masuishi t. Front Oncol. 2021 Mar 8;11:576036. doi: 10.3389/fonc.2021.576036. eCollection 2021. Front Oncol. 2021. PMID: 33763345 Free PMC article.
Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study).
Nishina T, Moriwaki T, Shimada M, Higashijima J, Sakai Y, Masuishi T, Ozeki M, Amagai K, Negoro Y, Indo S, Denda T, Sato M, Yamamoto Y, Nakajima G, Mizuta M, Takahashi I, Hiroshima Y, Ishida H, Maeba T, Hyodo I. Nishina T, et al. Among authors: masuishi t. Clin Colorectal Cancer. 2016 Sep;15(3):236-42. doi: 10.1016/j.clcc.2015.12.001. Epub 2015 Dec 17. Clin Colorectal Cancer. 2016. PMID: 26778644 Clinical Trial.
Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer.
Sunakawa Y, Yang D, Moran M, Astrow SH, Tsuji A, Stephens C, Zhang W, Cao S, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Masuishi T, Takeuchi M, Fujii M, Nakajima T, Ichikawa W, Lenz HJ. Sunakawa Y, et al. Among authors: masuishi t. Cancer Biol Ther. 2016 Jul 2;17(7):751-9. doi: 10.1080/15384047.2016.1178426. Epub 2016 Apr 22. Cancer Biol Ther. 2016. PMID: 27104867 Free PMC article.
Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102.
Hamauchi S, Yamazaki K, Masuishi T, Kito Y, Komori A, Tsushima T, Narita Y, Todaka A, Ishihara M, Yokota T, Tanaka T, Machida N, Kadowaki S, Fukutomi A, Ura T, Onozawa Y, Ando M, Tajika M, Muro K, Yasui H, Mori K, Taniguchi H. Hamauchi S, et al. Among authors: masuishi t. Clin Colorectal Cancer. 2017 Mar;16(1):51-57. doi: 10.1016/j.clcc.2016.07.005. Epub 2016 Jul 21. Clin Colorectal Cancer. 2017. PMID: 27522626
Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison.
Masuishi T, Taniguchi H, Hamauchi S, Komori A, Kito Y, Narita Y, Tsushima T, Ishihara M, Todaka A, Tanaka T, Yokota T, Kadowaki S, Machida N, Ura T, Fukutomi A, Ando M, Onozawa Y, Tajika M, Yasui H, Muro K, Mori K, Yamazaki K. Masuishi T, et al. Clin Colorectal Cancer. 2017 Jun;16(2):e15-e22. doi: 10.1016/j.clcc.2016.07.019. Epub 2016 Aug 31. Clin Colorectal Cancer. 2017. PMID: 27670892
Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody.
Hasegawa H, Taniguchi H, Mitani S, Masuishi T, Komori A, Narita Y, Kadowaki S, Ura T, Ando M, Yatabe Y, Muro K. Hasegawa H, et al. Among authors: masuishi t. Oncology. 2017;92(4):205-212. doi: 10.1159/000453336. Epub 2017 Feb 1. Oncology. 2017. PMID: 28142137 Clinical Trial.
Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer.
Komori A, Taniguchi H, Hamauchi S, Masuishi T, Kito Y, Narita Y, Tsushima T, Ishihara M, Todaka A, Tanaka T, Yokota T, Kadowaki S, Machida N, Ura T, Fukutomi A, Ando M, Onozawa Y, Tajika M, Yasui H, Muro K, Mori K, Yamazaki K. Komori A, et al. Among authors: masuishi t. Oncology. 2017;93(5):329-335. doi: 10.1159/000479280. Epub 2017 Sep 2. Oncology. 2017. PMID: 28866662
Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).
Kimura Y, Fujii M, Masuishi T, Nishikawa K, Kunisaki C, Matsusaka S, Segawa Y, Nakamura M, Sasaki K, Nagao N, Hatachi Y, Yuasa Y, Asami S, Takeuchi M, Furukawa H, Nakajima T; JACCRO GC-06 Study Group. Kimura Y, et al. Among authors: masuishi t. Gastric Cancer. 2018 May;21(3):421-427. doi: 10.1007/s10120-017-0766-x. Epub 2017 Sep 21. Gastric Cancer. 2018. PMID: 28936560 Free PMC article. Clinical Trial.
Correction to: Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC‑06).
Kimura Y, Fujii M, Masuishi T, Nishikawa K, Kunisaki C, Matsusaka S, Segawa Y, Nakamura M, Sasaki K, Nagao N, Hatachi Y, Yuasa Y, Asami S, Takeuchi M, Furukawa H, Nakajima T; JACCRO GC-06 Study Group. Kimura Y, et al. Among authors: masuishi t. Gastric Cancer. 2018 May;21(3):428. doi: 10.1007/s10120-017-0784-8. Gastric Cancer. 2018. PMID: 29234896 Free PMC article.
105 results